-
Henry Schein expects to name new CEO by mid-January 2026
-
BofA lists 16 stock opportunities away from AI
-
Henry Schein (HSIC) Tops Q3 EPS by 10c, provides guidance
-
Henry Schein One partners with AWS to integrate AI into dental platforms
-
Biomerica partners with Henry Schein to market IBS test in US
-
CFRA Downgrades Henry Schein (HSIC) to Strong Sell
-
Piper Sandler Reiterates Overweight Rating on Henry Schein (HSIC)
-
Evercore ISI Upgrades Henry Schein (HSIC) to Outperform
-
Henry Schein (HSIC) Misses Q2 EPS by 9c, Misses on Revenue; Offers FY25 EPS Guidance
-
Stifel Downgrades Henry Schein (HSIC) to Hold
-
Baird Downgrades Henry Schein (HSIC) to Neutral
-
Piper Sandler Highlights 'Best Value Stocks' in Medical Technology
-
Henry Schein (HSIC) announces KKR completes strategic investment, appoints Dan Daniel to Board
-
Henry Schein (HSIC) Tops Q1 EPS by 3c, provides guidance
-
Henry Schein (HSIC) PT Lowered to $76 at Mizuho
-
Henry Schein (HSIC) April 75 puts and April 80 calls active
-
Henry Schein (HSIC) Misses Q4 EPS by 4c, provides guidance
-
Wel;ls Fargo Starts Henry Schein (HSIC) Equal-weight
-
Henry Schein (HSIC) PT Raised to $78 at Mizuho
-
Henry Schein (HSIC) Announces Strategic Investment by KKR (KKR), Board Changes and Provides Preliminary Unaudited Financial Results and 2025 Financial Guidance
-
Activist Ananym Plans to Launch Proxy Fight at Henry Schein (HSIC) - Reuters
-
Henry Schein (HSIC) Completes Acquisition of Acentus
-
Mizuho Starts Henry Schein (HSIC) at Neutral
-
Henry Schein (HSIC) spreader of 2K contracts of December 70 puts and 1500 December 75 puts
-
Henry Schein (HSIC) to Acquire Acentus
-
Piper Sandler Reiterates Overweight Rating on Henry Schein (HSIC)
-
Activist Investor Ananym Capital Pushes for Changes at Henry Schein (HSIC) - Reuters
-
Henry Schein (HSIC) Tops Q3 EPS by 15c, provides guidance
-
The election implications for healthcare technology and distribution stocks - BofA
-
Zentek (ZTEK) Provides Market Update on ZenGUARD Antimicrobial Surgical Masks
-
Zentek Provides Market Update on ZenGUARD(TM) Antimicrobial Surgical Masks
-
CFRA Downgrades Henry Schein (HSIC) to Sell ,'see better near-term upside in pharmaceutical distributors'
-
Henry Schein (HSIC) Tops Q2 EPS by 1c ; Offers Guidance
-
Baird Upgrades Henry Schein (HSIC) to Outperform

